Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 1 results out of 1
Data Insights
(Ceftibuten + xeruborbactam) by Qpex Biopharma for Pyelonephritis: Likelihood of Approval
(Ceftibuten + xeruborbactam) is under clinical development by Qpex Biopharma and currently in Phase I for Pyelonephritis. According to GlobalData,...